Events
ESMO GI 2026: EMERALD trials paint mixed picture for TACE-immunotherapy combinations in hepatocellular carcinoma
- ESMO GI 2026: KRYSTAL-10 misses primary endpoints despite improved response rates in KRAS G12C-mutated metastatic colorectal cancer
- Rise in colorectal cancer among young adults in Germany as well — but below US levels
- ASCO 2026: EMERALD-3 study shows that new combination treatment strategies for embolization-eligible hepatocellular carcinoma are superior
S4 E5: ASCO 2026 Special Part 2
ASCO Special Part 2: Quick Bite Marathon! The Oncology Journal Club Podcast hosted by Professor Craig Underhill, Dr Kate Clarke…
Culture, silence and safety: why oncology cannot afford to ignore its workforce
By Dr Dominique Lee Public trust in oncology relies on strong professional standards, transparent governance, and confidence that concerns will be…








